...Great. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the conference today with Ionis. A little different format this year than in years past. So no switching rooms for Q&A. We're going to stay right in here. If you have a question, you can raise your hand, somebody will run over to you with a microphone. Or alternatively, you can submit questions electronically and I'll read them off the iPad up here. So with that out of the way, let me turn it over to Ionis CEO, Brett Monia. Brett P. Monia ...